Propanc Biopharma, Inc. (PPCB) is in Healthcare, Biotechnology, based in Australia, listed on NasdaqCM. Market cap 4.63M USD. 52-week range 0.4600 to 47.50 USD. Trailing P/E 0.0. Data as of 2026-10-09.
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the ...